Comparative Chemotherapeutic Activity of Amphotericin B and Amphotericin B Methyl Ester
AUTOR(ES)
Bonner, Daniel P.
RESUMO
The comparative efficacy of amphotericin B and amphotericin B methyl ester (AME) against experimental histoplasmosis, blastomycosis, cryptococcosis, and candidosis in mice was assessed by determining the effect of daily intraperitoneal therapy on 21-day survival and persistence of organisms in internal organs. AME, like amphotericin B, was effective against each of the experimental infections, but the efficacy was lower than the parent compound. For Histoplasma and Blastomyces infections the mean effective dose (ED50) of amphotericin B was 0.3 mg/kg, whereas the corresponding values for AME, respectively, were 2.4 and 2.8 mg/kg. For Cryptococcus infection the ED50 for amphotericin B was 0.2 mg/kg compared with 2.0 mg/kg for AME. The ED50 of amphotericin B for Candida infection was lower than 0.05 mg/kg and the value of AME was between 0.5 to 0.05 mg/kg. The colony counts from internal organs of the surviving animals after the therapeutic regimens were compatible with the data on survival.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=429217Documentos Relacionados
- Comparative In Vitro Antifungal Activity of Amphotericin B and Amphotericin B Methyl Ester
- Comparative in vitro and in vivo evaluation of N-D-ornithyl amphotericin B methyl ester, amphotericin B methyl ester, and amphotericin B.
- Comparative Susceptibility of Candida albicans to Amphotericin B and Amphotericin B Methyl Ester
- Comparative Toxicological Studies of Amphotericin B Methyl Ester and Amphotericin B in Mice, Rats, and Dogs
- Comparative Susceptibility of Four Kinds of Pathogenic Fungi to Amphotericin B and Amphotericin B Methyl Ester
